These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 2792946)

  • 1. [Treatment of hyperprolactinemia and acromegaly with lisuride].
    Berezin M; Elchalal U; Olchovsky D
    Harefuah; 1989 Jun; 116(12):634-7. PubMed ID: 2792946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dopamine agonists in the treatment of hyperprolactinemia. Comparison between bromocriptine and lisuride.
    Stracke H; Heinlein W; Horowski R; Schatz H
    Arzneimittelforschung; 1986 Dec; 36(12):1834-6. PubMed ID: 3566845
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The efficacy of lisuride in the treatment of hyperprolactinemic amenorrhea.
    Rojanasakul A; Sirimongkolkasem R; Chailurkit LO
    J Med Assoc Thai; 1990 Feb; 73 Suppl 1():42-6. PubMed ID: 2351912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effectiveness of lysenyl-forte treatment in acromegaly and hyperprolactinemia syndrome].
    Balabolkin MI; Gerasimov GA; Snigireva RIa; Gorokhova TR
    Klin Med (Mosk); 1989 Sep; 67(9):89-92. PubMed ID: 2586051
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term pergolide treatment of hyperprolactinemic patients previously unsuccessfully treated with dopaminergic drugs.
    Berezin M; Avidan D; Baron E
    Isr J Med Sci; 1991 Jul; 27(7):375-9. PubMed ID: 2071373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic treatment of pathological hyperprolactinemia and acromegaly with the new ergot derivative terguride.
    Dallabonzana D; Liuzzi A; Oppizzi G; Cozzi R; Verde G; Chiodini P; Rainer E; Dorow R; Horowski R
    J Clin Endocrinol Metab; 1986 Oct; 63(4):1002-7. PubMed ID: 3745401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of the new ergot derivative terguride on plasma PRL and GH levels in patients with pathological hyperprolactinemia or acromegaly.
    Dallabonzana D; Liuzzi A; Oppizzi G; Verde G; Chiodini PG; Dorow R; Horowski R
    J Endocrinol Invest; 1985 Apr; 8(2):147-51. PubMed ID: 4031381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of the dopamine agonist lisuride in the treatment of acromegaly and pathological hyperprolactinemic states.
    Verde G; Chiodini PG; Liuzzi A; Cozzi R; Favales F; Botalla L; Spelta B; Dalla Bonzana D; Rainer E; Horowski R
    J Endocrinol Invest; 1980; 3(4):405-14. PubMed ID: 6782153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Drug therapy of hyperprolactinemia, acromegaly and Cushing syndrome].
    Marek J; Rezábek K; Srámková J
    Z Gesamte Inn Med; 1983 Nov; 38(22):246-8. PubMed ID: 6666180
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lisuride hydrogen maleate: evidence for a long lasting dopaminergic activity in humans.
    Liuzzi A; Chiodini PG; Oppizzi G; Botalla L; Verde G; De Stefano L; Colussi G; Gräf KJ; Horowski R
    J Clin Endocrinol Metab; 1978 Feb; 46(2):196-202. PubMed ID: 108287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Terguride in the treatment of hyperprolactinemia and acromegaly].
    Marek J; Bauer J; Srámková J; Hána V
    Cas Lek Cesk; 1986 Jan; 125(4):100-5. PubMed ID: 3948223
    [No Abstract]   [Full Text] [Related]  

  • 12. Growth hormone and changes in the secretion of thyrotropic hormone after thyrotropin-releasing hormone (TRH): ineffectiveness of dopaminergic stimulation.
    Felt V; Nedvídková J
    Endokrinologie; 1982 Oct; 80(2):201-6. PubMed ID: 6819130
    [No Abstract]   [Full Text] [Related]  

  • 13. [Hyperprolactinemia syndrome in men].
    Balabolkin MI; Gerasimov GA; Gorokhova TR; Liubimov AV
    Sov Med; 1990; (4):23-6. PubMed ID: 2374967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Use of dironyl in the treatment of acromegaly and hyperprolactinemia].
    Felt V; Nedvídková J
    Vnitr Lek; 1985 Oct; 31(10):980-5. PubMed ID: 4090298
    [No Abstract]   [Full Text] [Related]  

  • 15. Dopaminergic treatment of acromegaly: different effects on hormone secretion and tumor size.
    Oppizzi G; Liuzzi A; Chiodini P; Dallabonzana D; Spelta B; Silvestrini F; Borghi G; Tonon C
    J Clin Endocrinol Metab; 1984 Jun; 58(6):988-92. PubMed ID: 6725515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term treatment of acromegaly with lisuride: differences of effect on growth hormone and somatomedin.
    Marek J; Srámková J; Schüllerová M; Stĕpán J; Schreiberová O
    Endokrinologie; 1981 Dec; 78(2-3):175-85. PubMed ID: 7037372
    [No Abstract]   [Full Text] [Related]  

  • 17. [Determination of growth hormone response to thyreoliberin in the evaluation of lisuride therapy of acromegaly].
    Felt V; Nedvídková J
    Vnitr Lek; 1982 Aug; 28(8):756-61. PubMed ID: 6814061
    [No Abstract]   [Full Text] [Related]  

  • 18. [Hyperprolactinemia and prolactinomas. Results of surgical and drug therapy].
    Brabant G; Brennecke I; Herrmann H; Friedrich H; Wagner TO; von zur Mühlen A; Hesch RD
    Dtsch Med Wochenschr; 1985 Oct; 110(41):1564-7. PubMed ID: 4042883
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Drug therapy of hyperprolactinemia and acromegaly].
    von Werder K; Eversmann T; Fahlbusch R; Rjosk HK
    Acta Med Austriaca; 1978; 5(3):61-3. PubMed ID: 377884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Experiences with bromocriptine treatment in acromegaly--a preliminary report.
    Nilsson A
    Acta Endocrinol Suppl (Copenh); 1978; 216():217-24. PubMed ID: 274038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.